Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 16, 2025, at 14:00 in the company's conference room located at No. 2 Huachang Road, East District, Changping Science Park, Beijing [1][4] - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's shareholder meeting online voting system [1][4] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's online voting system from 9:15 to 15:00 on the day of the meeting [1][5] - Specific voting times through the trading system are from 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1][5] - Shareholders must complete identity verification to vote online for the first time [5] Meeting Agenda - The meeting will review 14 proposals that have been approved by the company's board of directors and supervisory board [3][4] - The proposals include non-cumulative voting items and matters related to business registration changes [3][13] Attendance Requirements - Shareholders registered with the China Securities Depository and Clearing Corporation Limited by the close of trading on September 9, 2025, are eligible to attend [5][6] - Registration for attendance must be completed by September 13 and September 15, 2025 [6] Proxy Voting - Shareholders can appoint proxies to attend the meeting, with specific documentation required for both individual and corporate representatives [6][12] - Proxies must present identification and authorization documents to participate in the voting process [6][12]

Group 1 - The company reported a revenue of 248 million yuan for the first half of 2025, representing a year-on-year growth of 30.07% [1] - The net profit attributable to shareholders reached 71.4 million yuan, showing a significant increase of 102.9% compared to the previous year [1] - The basic earnings per share stood at 0.52 yuan [1]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 8月27日消息，佰仁医疗发布半年度报告。 责任编辑：小浪快报 公告显示，公司半年度营业收入248,028,217.88元，同比增加30.07%，归属上市公司股东的净利润 71,400,619.61元，同比增加102.9%。 ...

Group 1 - The core viewpoint of the report highlights the financial performance of Beijing Balancemed Medical Technology Co., Ltd. for the first half of 2025, showing significant growth in revenue and profit metrics [1][2]. - Total assets at the end of the reporting period amounted to approximately 1.45 billion RMB, reflecting a 1.62% increase compared to the end of the previous year [2]. - The company's operating income reached approximately 248 million RMB, representing a 30.07% increase year-on-year [2]. - The total profit for the period was approximately 76.4 million RMB, marking a substantial increase of 120.73% compared to the same period last year [2]. - The net profit attributable to shareholders of the listed company was approximately 61.4 million RMB, an increase of 88.55% year-on-year [2]. Group 2 - The report indicates that the company has a total of 3,426 shareholders as of the reporting period [3]. - The top ten shareholders include individuals and entities with varying ownership percentages, with the largest shareholder holding 61.21% of the shares [3][4]. - The report does not indicate any significant changes in the company's operational situation or any major events that would impact future operations [5].

Meeting Details - The third meeting of the supervisory board of Beijing Bairen Medical Technology Co., Ltd. was held on August 27, 2025, in a combined format of on-site and remote voting [1] - The meeting was convened by the chairwoman Wang Donghui, with all three supervisors present, ensuring compliance with relevant laws and the company's articles of association [1] Supervisory Board Resolutions - The supervisory board unanimously approved the proposal regarding the company's 2025 semi-annual report and its summary, confirming that the report's preparation and review procedures comply with legal regulations and internal control systems [2] - The content and format of the 2025 semi-annual report meet the requirements set by the China Securities Regulatory Commission and the Shanghai Stock Exchange, reflecting the company's true, accurate, and complete status [2] - The board also approved the proposal to abolish the supervisory board, transferring its powers to the audit committee of the board of directors, with the relevant rules being nullified [2]

Core Viewpoint - Beijing Balancemed Medical Technology Co., Ltd. plans to hold a semi-annual performance briefing on September 4, 2025, to discuss its 2025 semi-annual report and address investor concerns [1][2]. Group 1: Meeting Details - The performance briefing will take place on September 4, 2025, from 10:00 AM to 11:00 AM [1][3]. - The meeting will be held at the Shanghai Stock Exchange's "SSE Roadshow Center" and will be conducted in an interactive online format [1][3]. - Participants will include the company's Chairman and General Manager, Jin Lei, along with other key executives [1]. Group 2: Investor Participation - Investors can participate online through the SSE Roadshow Center during the scheduled time [2][3]. - Questions can be submitted by investors from August 28, 2025, to September 3, 2025, before 4:00 PM, either through the SSE Roadshow Center or via the company's email [2][3]. - The company will address commonly asked questions during the briefing [2][3]. Group 3: Contact Information - The contact person for inquiries is Wang Lili, reachable at phone number 010-60735931 or via email at ir@balancemed.cn [2].

Core Points - The internal audit system of Beijing Baijun Medical Technology Co., Ltd. aims to standardize internal audit work, clarify responsibilities, ensure audit quality, and enhance economic efficiency [1][2] - The internal audit is defined as an independent and objective evaluation of financial activities, internal controls, and risk management to promote governance and achieve organizational goals [1][2] - The internal audit's objectives include improving internal controls, managing costs effectively, enhancing operational management, mitigating operational risks, and increasing company value [1][2] Chapter Summaries Chapter 1: General Principles - The internal audit system is established to comply with relevant laws and regulations, ensuring the integrity of financial reporting and internal controls [1][2] - Internal controls are defined as processes that provide reasonable assurance regarding the achievement of objectives related to operational efficiency, compliance, and asset security [1] Chapter 2: Audit Institutions and Personnel - The board of directors is responsible for establishing and implementing internal control systems, with significant internal control systems requiring board approval [2] - An audit committee is established by the board, consisting of directors, with independent directors making up more than half and at least one being a professional accountant [2][3] - The internal audit department is responsible for supervising the authenticity and completeness of financial information and internal control systems [2][3] Chapter 3: Responsibilities and General Requirements - The audit committee guides and supervises the internal audit department, reviews annual audit plans, and reports on audit progress and significant issues to the board [2][3] - The internal audit department evaluates the completeness and effectiveness of internal control systems across the company and its subsidiaries [3][4] Chapter 4: Specific Implementation - The internal audit department must conduct evaluations of internal controls at least annually and report findings to the audit committee [6][7] - Audits of significant external investments, asset purchases, guarantees, and related transactions must be conducted promptly, focusing on compliance with approval procedures and contract execution [8][9][10] Chapter 5: Violations and Responsibilities - Violations of laws, regulations, or internal policies may result in penalties, including administrative or economic sanctions for individuals involved in misconduct [10][12] Chapter 6: Supplementary Provisions - The internal audit system will be interpreted and revised by the board of directors and will take effect upon board approval [11]

北京佰仁医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开第三届董事会第十一次会议，审议通过了《关于取消公司监事会的议案》 《关于变更公司注册资本、修订 <公司章程> 并办理工商变更登记的议案》，同 日召开第三届监事会第八次会议，审议通过了《关于取消公司监事会的议案》。 现将有关情况说明如下： 证券代码：688198 证券简称：佰仁医疗 公告编号：2025-028 北京佰仁医疗科技股份有限公司 关于变更公司注册资本、取消监事会、修订《公司 章程》并办理工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、变更公司注册资本的情况 公司于 2025 年 6 月 13 日召开第三届董事会第十次会议、第三届监事会第 七次会议，审议通过了《关于公司 2020 年限制性股票激励计划首次授予部分第 五个归属期符合归属条件的议案》《关于公司 2020 年限制性股票激励计划预留 授予部分第三个归属期符合归属条件的议案》。2025 年 7 月 23 日，公司 2020 年 限制性股票激励计划首次授 ...

北京佰仁医疗科技股份有限公司 信息披露管理制度 北京佰仁医疗科技股份有限公司 信息披露管理制度 第一章 总则 第一条 为提高北京佰仁医疗科技股份有限公司（以下简称"公司"）的信息 披露质量，规范公司的信息披露行为，保护投资者的合法权益，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、《上海证券交易所科创板股票上 市规则》（以下简称"《科创板上市规则》"）、中国证券监督管理委员会（以下 简称"中国证监会"）发布的《上市公司信息披露管理办法》、《科创板上市公司 持续监管办法（试行）》等法律、法规、规范性文件以及《北京佰仁医疗科技股 份有限公司章程》（以下简称"公司章程"）等相关制度规定，结合公司实际情况， 制定本制度。 第二条 本制度所称"信息披露"是指公司将对公司股票及其衍生品种交易价 格可能产生较大影响而投资者尚未得知的信息，在规定的期限内，通过指定的媒 体，以规定的方式向社会公众公布，并按照规定报送证券监管部门。 第二章 信息披露的基本原则和一般规定 第一节 基本原则 第三条 信息披露义务人应当真实、准确、完整、及时地披露信息，不得有 虚假记载、误导性陈述或者重大遗漏。 公司和相关信息披露义务人应 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2025-031 序号 制度名称 情况 会审议 北京佰仁医疗科技股份有限公司 关于制定及修订部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京佰仁医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 第三届董事会第十一次会议，审议通过了关于制定及修订公司相关治理制度的议案， 具体情况如下： 公司根据现行有效的《中华人民共和国公司法》《中华人民共和国证券法》等 法律法规、规范性文件的相关规定，为进一步促进公司规范运作，结合公司自身实 际情况，拟制定及修订公司部分治理制度，具体情况如下表所示： 变更 是否需要股东大 《公司董事、高级管理人员所持公司股份及其 变动管理制度》 注：《股东大会议事规则》将更名为《股东会议事规则》。 公司本次修订的上述治理制度中，第 3 项至第 16 项制度和第 25 项制度全文与 本公告同日在上海证券交易所网站（www.sse.com.cn）予以披露。 特此公告。 北京佰仁医疗科技股份有限公司董事会 ...